-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SrDfVC8SZ1hNwPqTs6azPrfZRbQGExzL5Q+qcxmQuhv5KZ8uQsT92Sbrp3BELBVH 5WUObJoFvNmTG7Rj4flWFg== 0000947871-07-001425.txt : 20071114 0000947871-07-001425.hdr.sgml : 20071114 20071114162528 ACCESSION NUMBER: 0000947871-07-001425 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20071114 DATE AS OF CHANGE: 20071114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRILL LYNCH PIERCE FENNER & SMITH INC CENTRAL INDEX KEY: 0000728612 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-89355 FILM NUMBER: 071245222 BUSINESS ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER CITY: NEW YORK STATE: NY ZIP: 10080 BUSINESS PHONE: 2126702273 MAIL ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER CITY: NEW YORK STATE: NY ZIP: 10080 424B3 1 f424b3_110807-biotech.htm

 

PROSPECTUS SUPPLEMENT

REGISTRATION NO. 333-89355

(To Prospectus dated August 15, 2007)

Filed Pursuant to Rule 424(b)(3)

 

 

 

1,000,000,000 Depositary Receipts

Biotech HOLDRS (SM) Trust

This prospectus supplement supplements information contained in the prospectus dated August 15, 2007 relating to the sale of up to 1,000,000,000 depositary receipts by the Biotech HOLDRS (SM) Trust.

The share amounts specified in the table in the “Highlights of Biotech HOLDRS” section of the base prospectus shall be replaced with the following:

 

Name of Company

Ticker

Share
Amounts

Primary
Trading
Market

Affymetrix, Inc.

AFFX

4

NASDAQ

Alkermes, Inc.

ALKS

4

NASDAQ

Amgen Inc.

AMGN

64.48

NASDAQ

Applera Corporation—Applied Biosystems Group*

ABI

18

NYSE

Applera Corporation—Celera Genomics Group*

CRA

4

NYSE

Biogen IDEC Inc.

BIIB

26.95

NASDAQ

Enzon Pharmaceuticals, Inc.

ENZN

3

NASDAQ

Genentech, Inc.

DNA

88

NYSE

Genzyme Corporation

GENZ

14

NASDAQ

Gilead Sciences, Inc.

GILD

64

NASDAQ

Human Genome Sciences, Inc.

HGSI

8

NASDAQ

Millennium Pharmaceuticals, Inc.

MLNM

12

NASDAQ

QLT Inc.

QLTI

5

NASDAQ

Sepracor Inc.

SEPR

6

NASDAQ

Shire p.l.c.

SHPGY

6.8271

NASDAQ

 

 

 

 

 

* The securities of this company trade as a tracking stock. Please see “Risk Factors” and the business description in Annex A for additional information relating to an investment in tracking stock.

 

The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.

 

The date of this prospectus supplement is September 30, 2007.

 

 

 

 GRAPHIC 2 img1.gif GRAPHIC begin 644 img1.gif M1TE&.#EA2P%7`'<``"'_"TU33T9&24-%.2XP#0````%S4D="`*[.'.D`(?\+ M35-/1D9)0T4Y+C`8````#&US3U!-4T]&1DE#13DN,!.;*91D`"P`````2P%7 M`(0O?[\P?[\P?\`P@,"_O[^PL+"OKZ^@H*#?W]_0T-#/S\_`P,#OD`#@CP#@ MD`#P\/#O[^_@X.#___\!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,! M`@,!`@,!`@,%_Z`DCF1IGFBJKFSKOG`LSW1MWWBN[WSO_\"@<$@L&H_(I'+) M;#J?T*AT2JU:K]BL=LOM>K_@L'A,+IO/Z+1ZS6Z[W_"X?$ZOV^_XO'[/[_O_ M@'0/$H,DA82!B8J+C(U&@P(``P&1DY64B"*'CIR*`9^@`2.AH9VFBI<"F8B# M#ZZ2E`"MJZ>U=*4HLZVDL[:^<98CNJS$K@^P`@\0KL2_SF:@AL+3*:#&S<_9 M89(GP[TED+#+UYO:YG6AQN7G['.6LNKM\G/IU_//#`T,#ODS^OP-M%QRM6P$ MP'T,A!Q5'H'`G$F3YHV:.'&FS,D3YG3#-RA#HU M)HRJ&[.&="BA:,F@,L#.^"2DI.]_J1`OTI5"*_KC.F#0D MU@!C!44P5`BR154:7ET\#?O0S\RX;6.0+6OVT.,@:5G4A&Q55Q[Y M!>X4\>W/OX/U:?]_I@5`70_(``#!@==I0@C_:S^,9Y]MT.DU6W@/^I?5CS\9 M\MT/W1G66`P7SMA12D8FF8:+<*U`5CP^D!(`CSW"IR(.5^*WGPI,LFA,6"V9Y0DJ6G-=E3E( MJ4R;@0'Z9PV+KKBEEF#J6<2C7V#X`ITC5`+8@<6L^LZ->*UFNZ')ZHK!8 M(CN"EU<]NMFK\'KA:@N8OH/`OX3*$,ZG`?R+@)LNJ,J#LB1LA)BX)3A\+(UG MD/NNI!*`\NS!Z=;P0*Z?;/QLM,&"J5^D\EJ9[[TMHHRQF`R?T)U?`21@\Z@V MT'R)P1$@P*NW>19Y:=!\8D1#MZUFRT*20?N9\KSSD:+``@E$0,MN(->=(=(HT%G@`@LHT#$,TU9B>.(0LV#^ MO<;TA6I8G&+4I!!0-B,S@"X;8]ZJ>A(]__6 M_Y)Z]3VH1PDR`FE>ZS@H"DR]]9NIUW[$,01?TF/NP,T!VR[\AZ\7GRO; MOW-]]_#,P]#;QZ'GSGONLE?M\_+-9U^#\=P'T';;"G`,@?8E_):Q*"+\9GSZ MN*RWGBF#2"\_YP,40`#R;KMIM_8Z2W#:_-&+1<9"-\!,`>`7W0.9_0B0O(-] M@WRC4!_ZW(>^C$6P0Q0\G_D4\3Q"3(]^`3"``0K`MME]3AK8DX>.)!`)$;10 M!-P0P5%DZ!<8SI`$T_)%(3YFO`.(T'[)@Q8U(%B^"8IB,AE,7P2+N,0DGD(7 M/5-``9!A@`-8T8HB%.']$%"U_1&1!/W[7_]<:,"2=PP0&>E3A0L/^`R"1&!J M!"#`"$=H/ZK];AR,^^(%D5C!#5J0?>WKT/F6:`YG]J,E.>O*35:".*%?!25":,@66/-TI5XE"<*@RE:R, KI2QG2 -----END PRIVACY-ENHANCED MESSAGE-----